Evidence map›Paper›PMID 34274493›Full record

ArticleTransplantation and cellular therapy2021

A Fructo-Oligosaccharide Prebiotic Is Well Tolerated in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: A Phase I Dose-Escalation Trial.

Tessa M Andermann, Farnaz Fouladi, Fiona B Tamburini, Bita Sahaf, Ekaterina Tkachenko, Courtney Greene, Matthew T Buckley, Erin F Brooks, Haley Hedlin, Sally Arai and 6 more

Open access · greenAbstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Transplantation and cellular therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 2 pooled it
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 38 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Therapeutic properties of plant-derived prebiotics in melanoma.Exploration of targeted anti-tumor therapy · 2025
    Review
  18. The Microbiome and Pediatric Transplantation.Journal of the Pediatric Infectious Diseases Society · 2024
    Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 1 country.

Tessa M AndermannDivision of Infectious Diseases, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Farnaz FouladiDepartment of Bioinformatics and Genomics, University of North Carolina at Charlotte, Charlotte, North Carolina.
Fiona B TamburiniDepartment of Genetics, Department of Medicine, Stanford University, Stanford, California.
Bita SahafDivision of Blood and Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University, Stanford, California.
Ekaterina TkachenkoStanford University School of Medicine, Stanford University, Stanford, California.
Courtney GreeneDivision of Blood and Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University, Stanford, California.
Matthew T BuckleyDepartment of Genetics, Department of Medicine, Stanford University, Stanford, California.
Erin F BrooksDivision of Hematology, Department of Medicine, Stanford University, Stanford, California.
Haley HedlinQuantitative Sciences Unit, Department of Medicine, Stanford University, Stanford, California.
Sally AraiDivision of Blood and Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University, Stanford, California.
Crystal L MackallDivision of Hematology/Oncology, Department of Pediatrics, Stanford University, Stanford, California.
David MiklosDivision of Blood and Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University, Stanford, California.
Robert S NegrinDivision of Blood and Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University, Stanford, California.
Anthony A FodorDepartment of Bioinformatics and Genomics, University of North Carolina at Charlotte, Charlotte, North Carolina. Electronic address: arezvani@stanford.edu.
Andrew R RezvaniDivision of Blood and Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University, Stanford, California. Electronic address: asbhatt@stanford.edu.
Ami S BhattDepartment of Genetics, Department of Medicine, Stanford University, Stanford, California; Division of Blood and Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University, Stanford, California. Electronic address: afodor@uncc.edu.
Stanford University · USUniversity of North Carolina at Charlotte · USUniversity of North Carolina at Chapel Hill · US

Funding

Stanford Center for Clinical & Translational Education and Research (Spectrum)UL1TR003142 · NCATS · STANFORD UNIVERSITY · PI O'HARA, RUTH M · 2019 to 2023
$45.0M
Spectrum Stanford Center for clinical and Translational Research and EducationUL1TR001085 · NCATS · STANFORD UNIVERSITY · PI CULLEN, MARK RICHARD, GREENBERG, HARRY BERNARD · 2013 to 2017
$37.1M
Institutional Career Development Core (KL2)KL2TR003143 · NCATS · STANFORD UNIVERSITY · PI ASCH, STEVEN M. · 2019 to 2023
$8.7M
Spectrum Stanford Center for clinical and Translational Research and EducationKL2TR001083 · NCATS · STANFORD UNIVERSITY · PI CULLEN, MARK RICHARD, GREENBERG, HARRY BERNARD · 2013 to 2017
$4.9M
Culture-free pathogen tracking in hospitalized patientsR01AI143757 · NIAID · STANFORD UNIVERSITY · PI BHATT, AMI SIDDHARTH · 2020 to 2023
$3.0M
Precision characterization of antimicrobial resistance gene dynamics in bloodstream infection risk after hematopoietic stem cell transplantationK23AI163365 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ANDERMANN, TESSA · 2021 to 2025
$1.0M
Sequence-based pathogen discovery in post-stem cell transplantation syndromesK08CA184420 · NCI · STANFORD UNIVERSITY · PI BHATT, AMI SIDDHARTH · 2014 to 2017
$524k
NCATS NIH HHS KL2 TR001083NCATS NIH HHS KL2 TR003143NCATS NIH HHS UL1 TR001085NCATS NIH HHS UL1 TR003142NCI NIH HHS K08 CA184420NIAID NIH HHS K23 AI163365NIAID NIH HHS R01 AI143757
6 · The paper itself

Abstract

Alterations of the gut microbiota after allogeneic hematopoietic cell transplantation (allo-HCT) are a key factor in the development of transplant-related complications such as graft-versus-host disease (GVHD). Interventions that preserve the gut microbiome hold promise to improve HCT-associated morbidity and mortality. Murine models demonstrate that prebiotics such as fructo-oligosaccharides (FOSs) may increase gut levels of short-chain fatty acids (SCFAs) such as butyrate and consequently induce proliferation of immunomodulatory FOXP3

Indexed as

Gastrointestinal MicrobiomeGraft vs Host DiseaseHematopoietic Stem Cell TransplantationAnimalsHumansMiceOligosaccharidesPrebioticsOligosaccharidesPrebioticsBlood and Marrow TransplantationBMTFructo-oligosaccharidesGraft-versus-host diseaseGVHDHCTHematopoietic stem cell transplantationHSCTMicrobiomePrebioticShotgun metagenomic sequencing

Identifiers

PMID34274493
PMCPMC8556222
OpenAlexW3180185215

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.